Please use this identifier to cite or link to this item:
Title: Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis
Author: Cobo Dols, Manuel
Beato Zambrano, Carmen
Cabezón Gutiérrez, Luis
Chicas Sett, Rodolfo
Blancas López-Barajas, María Isabel
García Navalón, Francisco
Fírvida Pérez, José Luis
Serrano Bermúdez, Gala
Togores Torres, Pilar
Delgado Mingorance, Ignacio
Giraldo Marín, Alexandra
Librán Oriol, Anna
Paredes Lario, Alfredo
Sánchez Mauriño, Pedro
Higuera Gómez, Oliver
Moreno Muñoz, Diana
Jiménez López, Antonio Javier
Huerta González, Ibone
Sanz Yagüe, Almudena
Soler López, Begoña
Keywords: Càncer
Issue Date: 6-May-2020
Publisher: BMJ
Abstract: Objectives: Opioid-induced constipation (OIC) can affect up to 63% of all patients with cancer. The objectives of this study were to assess quality of life as well as efficacy and safety of naloxegol, in patients with cancer with OIC. Methods: An observational study was made of a cohort of patients with cancer and with OIC exhibiting an inadequate response to laxatives and treated with naloxegol. The sample consisted of adult outpatients with a Karnofsky performance status score ≥50. The Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) and the Patient Assessment of Constipation Symptoms (PAC-SYM) were applied for 3 months. Results: A total of 126 patients (58.2% males) with a mean age of 61.3 years (range 34-89) were included. Clinically relevant improvements (>0.5 points) were recorded in the PAC-QOL and PAC-SYM questionnaires (p<0.0001) from 15 days of treatment. The number of days a week with complete spontaneous bowel movements increased significantly (p<0.0001) from 2.4 to 4.6 on day 15, 4.7 after 1 month and 5 after 3 months. Pain control significantly improved (p<0.0001) during follow-up. A total of 13.5% of the patients (17/126) presented some gastrointestinal adverse reaction, mostly of mild (62.5%) or moderate intensity (25%). Conclusions: Clinically relevant improvements in OIC-related quality of life, number of bowel movements and constipation-related symptoms were recorded as early as after 15 days of treatment with naloxegol in patients with cancer and OIC, with a good safety profile.
Note: Reproducció del document publicat a:
It is part of: BMJ Supportive & Palliative Care, 2020, vol. 11, num. 1, p. 25-31
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
bmjspcare-2020-002249.full.pdf508.04 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons